

Infectious Risk of Immunosuppressive Medications in Dermatology

	Therapies	Infectious Risk
Group A	Secukinumab (Cosentyx) Ixekizumab (Taltz) Brodalumab (Siliq) Guselkumab (Tremfya) Tildrakizumab-asmn (Ilumya) Risankizumab-rzaa (Skyrizi) Dupilumab (Dupixent)	No effect on viral immunity
Group B	Ustekinumab (Stelara) Apremilast (Otezla)	Theoretical effect on T _h 1/viral immunity, but no actual increased incidence of viral infections while on drug
Group C	Etanercept (Enbrel) Infliximab (Remicade) Adalimumab (Humira) Certolizumab pegol (Cimzia) Tofacitinib (Xeljanz) Baricitinib (Olumiant) Upadacitinib (Rinvoq)	Slight increased risk of infections in general, including viral infections
Group D	Prednisone Methotrexate Cyclosporine Azathioprine Mycophenylate mofetil	More broad-based immunosuppression, which would increase risk of infections, including viral infections
Reference: Data in this table is provided by and based upon Dr. Andrew Blauvelt's clinical experience and review of the literature.		